ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2026, Vol. 35 ›› Issue (1): 15-21.DOI: 10.3969/j.issn.1006⁃298X.2026.01.003

• 论著 • 上一篇    下一篇

含糖透析液对维持性血液透析患者血糖的影响:前瞻性、多中心、随机对照研究

  

  • 出版日期:2026-02-27 发布日期:2026-02-27

Influence on blood glucose in maintenance hemodialysis patients using glucose⁃containing dialysate:a prospective, multicenter, randomized controlled study

  • Online:2026-02-27 Published:2026-02-27

摘要: 目的:评估含糖透析液对维持性血液透析 (MHD) 患者血糖的影响与安全性。 方法:采用前瞻性、单盲、多中心、分层随机对照的非劣效性试验设计。将纳入的 260 例患者 (糖尿病亚组 176 例,非糖尿病亚组 84 例) 随机分为试验组 (含糖透析液) 和对照组 (无糖透析液), 两组均进行单次血液透析治疗。主要评价指标为透析后电解质⁃酸碱复合达标率 (非劣效性) 及糖尿病亚组透析期间低血糖发生率 (优效性)。次要评价指标包括总体低血糖发生率、透析充分性 (透析后尿素氮和肌酐下降率) 及安全性指标 (实验室检查、生命体征和不良事件)。 结果:主要评价指标表明,试验组透析后电解质⁃酸碱复合达标率非劣于对照组 (非劣效成立), 且糖尿病亚组透析期间低血糖发生率显著低于对照组(P=0.000);次要评价指标显示试验组总体低血糖发生率更低(P=0.000);两组患者透析后尿素氮、肌酐下降率差异无统计学意义;在安全性方面,试验组不良事件发生率低于对照组(P=0.015),其余安全性指标无统计学差异。结论:含糖透析液在患者中的疗效非劣于无糖透析液,且显著降低糖尿病亚组的低血糖风险,安全性良好,具有临床推广价值。

关键词: 含糖透析液, 维持性血液透析, 糖尿病, 低血糖, 非劣效性分析

Abstract: Objective:To evaluate the efficacy and safety of glucose⁃containing dialysate in maintenance hemodialysis (MHD) patients. Methods:A prospective, single⁃blind, multicenter, stratified, randomized controlled non⁃inferiority trial was conducted. A total of 260 patients (including 176 in the diabetes subgroup and 84 in the non⁃diabetes subgroup) were randomized into either the experimental group (glucose⁃containing dialysate) or the control group (glucose⁃free dialysate). Both groups underwent a single hemodialysis session. The primary endpoints were the post⁃dialysis electrolyte⁃acid⁃base composite target attainment rate (non⁃inferiority) and the incidence of intradialytic hypoglycemia in the diabetes subgroup (superiority). Secondary endpoints included the overall incidence of hypoglycemia, dialysis adequacy (post⁃dialysis reduction rate of blood urea nitrogen and creatinine), and safety indicators (laboratory tests, vital signs, and adverse events). Results:For the primary endpoints, the post⁃dialysis electrolyte⁃acid⁃base composite reaching the standard after dialysis in the experimental group was non⁃inferior to that in the control group (non⁃inferiority established), and the incidence of intradialytic hypoglycemia in the diabetes subgroup was significantly lower in the experimental group (P=0.000). Regarding secondary endpoints, the overall incidence of hypoglycemia was lower in the experimental group (P=0.000). There was no statistically significant difference in the post⁃dialysis reduction rates of blood urea nitrogen and creatinine between the two groups. In terms of safety, the incidence of adverse events was lower in the experimental group (P=0.015), while no statistically significant differences were observed in other safety indicators. Conclusion: The efficacy of glucose⁃containing dialysate in MHD patients is non⁃inferior to glucose⁃free dialysate. Furthermore, it significantly reduces the risk of hypoglycemia in the diabetes subgroup and demonstrates a favorable safety profile, indicating its value for clinical promotion.

Key words: glucose?containing dialysate, maintenance hemodialysis, diabetes, hypoglycemia, non?inferiority analysis